StreetInsider.com News Articles

Form F-3 Virax Biolabs Group Ltd

Fri, 24 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260724/26813792.html

Form F-3 Virax Biolabs Group Ltd

Fri, 24 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260724/26813792.html

Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mon, 20 Jul 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / July 20, 2026 / RedChip Companies aired interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Virax Biolabs Group Ltd. (Nasdaq:VRAX) on the RedChip Small Stocks, Big Money^™ show, a sponsored weekly television program that airs nationally on Bloomberg TV and CNBC. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.

Access the interviews in their entirety at:

Jeffrey Smith, Senior Vice President of Sales and Marketing

Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mon, 20 Jul 2026 09:00:00 -0400

Access the interviews in their entirety at:

Jeffrey Smith, Senior Vice President of Sales and Marketing

Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mon, 20 Jul 2026 09:00:00 -0400

Access the interviews in their entirety at:

Jeffrey Smith, Senior Vice President of Sales and Marketing

Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mon, 20 Jul 2026 09:00:00 -0400

Access the interviews in their entirety at:

Jeffrey Smith, Senior Vice President of Sales and Marketing

Form 6-K Virax Biolabs Group Ltd For: Jul 16

Thu, 16 Jul 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260716/26776729.html

Form 6-K Virax Biolabs Group Ltd For: Jul 16

Thu, 16 Jul 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260716/26776729.html

Virax Biolabs reports cash of $6.4M, regains Nasdaq compliance

Thu, 16 Jul 2026 07:30:25 -0400

Virax Biolabs Group Limited (NASDAQ: VRAX) filed its fiscal year 2026 annual report on July 2, 2026, reporting cash of $6.4 million, total assets of $8.3 million, total liabilities of $1.0 million, and shareholders' equity attributable to ordinary shareholders of $7.3 million as of March 31, 2026.

Research and development expenses rose to $3.7 million in fiscal 2026 from $2.0 million in fiscal 2025, while general and administrative expenses fell to $2.7 million from $4.0 million. Net loss narrowed to $5.0 million from $6.1 million in the prior year.

Subsequent to fiscal year end, the company completed the exercise of preferred investment

Virax Biolabs reports cash of $6.4M, regains Nasdaq compliance

Thu, 16 Jul 2026 07:30:25 -0400

Subsequent to fiscal year end, the company completed the exercise of preferred investment

Virax Biolabs reports cash of $6.4M, regains Nasdaq compliance

Thu, 16 Jul 2026 07:30:25 -0400

Subsequent to fiscal year end, the company completed the exercise of preferred investment

Virax Biolabs reports cash of $6.4M, regains Nasdaq compliance

Thu, 16 Jul 2026 07:30:25 -0400

Subsequent to fiscal year end, the company completed the exercise of preferred investment

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Thu, 16 Jul 2026 07:30:00 -0400

Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 million
Fosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian markets
Preferred investment option exercise, completed July 10, 2026, generated approximately $3.3 million in gross proceeds, further strengthening the Company's liquidity position and balance sheet
Nasdaq confirmed on July 13, 2026, that the Company regained compliance with the minimum bid price requirement